Novo Nordisk A/S (NYSE:NVO) Shares Up 1.9% – Here’s Why

Novo Nordisk A/S (NYSE:NVO) rose 1.9% during trading on Wednesday . The company traded as high as $38.19 and last traded at $37.6190. Approximately 13,533,612 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 23,541,123 shares. The stock had previously closed at $36.91.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a higher‑dose Wegovy injection (Wegovy HD 7.2 mg) nationwide in the U.S.; the dose is positioned to deliver greater weight loss than prior Wegovy doses, which could boost prescription volumes and revenue per patient. Novo Nordisk launches higher-dose Wegovy in the United States
• Positive Sentiment: Company says Wegovy HD is now available across the U.S.; media coverage (WSJ, Seeking Alpha) highlights the launch as a major commercial step that can accelerate the obesity franchise recovery. Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S.
• Positive Sentiment: Management continues buybacks under a DKK15bn repurchase programme initiated Feb 4 — a direct capital‑allocation action that supports the share price by reducing float and returning cash to shareholders. Novo Nordisk A/S – Share repurchase programme
• Positive Sentiment: Early reporting and coverage suggest the oral Wegovy pill is expanding the obesity treatment market by attracting new patients (not just switching injectables), which can increase the total addressable market for GLP‑1 therapies. Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
• Neutral Sentiment: Market commentary assessing Novo’s valuation after recent share‑price volatility highlights mixed short‑term returns and reiterates Novo’s large scale in diabetes, obesity and rare diseases; useful context for investors weighing risk vs. long‑term growth. Assessing Novo Nordisk (CPSE:NOVO B) Valuation After Recent Share Price Volatility
• Neutral Sentiment: Coverage (CNBC, YouTube) shows patient-level adoption stories for the Wegovy pill — positive for demand signals but anecdotal; broader prescription trends and payer coverage will determine material impact. Why Novo Nordisk’s Weight Loss Pill Has Taken Off
• Negative Sentiment: Competition: media note growing competition in the oral obesity-pill space (notably from Eli Lilly), which could pressure pricing, market share, or growth cadence if rivals capture meaningful patient volume. Can Wegovy HD 7.2 mg drive Novo Nordisk’s obesity drug rebound?

Analysts Set New Price Targets

NVO has been the topic of a number of research analyst reports. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Finally, Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Four equities research analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Trading Up 1.9%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company’s fifty day simple moving average is $42.36 and its 200-day simple moving average is $49.38. The company has a market capitalization of $167.97 billion, a P/E ratio of 10.84, a PEG ratio of 8.75 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 50.14%.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently modified their holdings of NVO. True Wealth Design LLC boosted its holdings in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares in the last quarter. Guerra Advisors Inc bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $25,000. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $25,000. WealthCollab LLC boosted its holdings in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares in the last quarter. Finally, American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $28,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.